2501 ORAL A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer. (September 2015) - Montgomery, B.; Joshua, A.; Gleave, M.; Fleshner, N.; Bubley, G.; True, L.; Tretiakova, M.; Wu, K.; Novotny, W.; Peterson, A.; Amelsberg, A.; Taplin, M.E.